NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd.

The Swiss pharma will base cardiometabolic drug research at the new Allston site. Elsewhere, AskBio advanced a gene therapy ...

Highlights,Institutional firms have modified their holdings in Biohaven Ltd., contributing to shifts in stock ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed” data ...

NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

A roundup of the most newsworthy healthcare press releases from PR Newswire, including business strategies shaping the future ...

Royal Bank of Canada restated their outperform rating on shares of Biohaven (NYSE:BHVN – Free Report) in a report published ...

Biohaven Ltd. (NYSE:BHVN – Get Free Report) fell 6.1% during mid-day trading on Monday after the company announced weaker ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd ("Biohaven" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Media are invited to join the Honourable Diane Lebouthillier, Minister of Fisheries, Oceans and the Canadian Coast Guard and Member of Parliament for Gaspésie?Les Îles-de-la-Madeleine, on behalf of ...

Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.